cenegermin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
growth factors 5235 1772578-74-1

Description:

MoleculeDescription

Synonyms:

  • cenegermin
  • oxervate
Cenegermin is a recombinant form of human nerve growth factor. Nerve growth factor is an endogenous protein involved in the differentiation and maintenance of neurons, which acts through specific high-affinity (i.e., TrkA) and low-affinity (i.e. p75NTR) nerve growth factor receptors. Nerve growth factor receptors are expressed in the anterior segment of the eye (cornea, conjunctiva, iris, ciliary body, and lens), by the lacrimal gland, and by posterior segment intraocular tissues. The treatment with cenegermin, administered as eye drops, is intended to allow restoration of corneal integrity.
  • Molecular weight: 13261.10
  • Formula: C583H902N166O173S8
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA: 5485.74
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
July 6, 2017 EMA Dompe farmaceutici s.p.a.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Eye pain 1707.41 76.16 354 1980 43814 90582299
Eye irritation 454.66 76.16 116 2218 33862 90592251
Ocular hyperaemia 358.34 76.16 96 2238 33702 90592411
Ocular discomfort 265.63 76.16 55 2279 6315 90619798
Photophobia 261.39 76.16 68 2266 21201 90604912
Eyelid pain 226.35 76.16 35 2299 748 90625365
Periorbital pain 200.02 76.16 28 2306 290 90625823
Product dose omission issue 195.04 76.16 110 2224 291577 90334536
Eye swelling 165.04 76.16 51 2283 29335 90596778
Vision blurred 154.91 76.16 69 2265 110224 90515889
Therapy interrupted 142.05 76.16 52 2282 50056 90576057
Lacrimation increased 135.34 76.16 43 2291 27019 90599094
Corneal deposits 124.94 76.16 19 2315 361 90625752
Eye discharge 113.94 76.16 29 2305 8229 90617884
Foreign body sensation in eyes 111.65 76.16 24 2310 3276 90622837
Product administration error 99.90 76.16 34 2300 26389 90599724
Swelling of eyelid 99.64 76.16 24 2310 5430 90620683
Eye infection bacterial 83.18 76.16 13 2321 297 90625816

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Eye pain 618.21 104.16 125 759 16905 42603546
Eye irritation 198.22 104.16 46 838 11272 42609179
Ocular hyperaemia 148.18 104.16 39 845 15924 42604527
Ocular discomfort 112.92 104.16 23 861 3034 42617417
Photophobia 105.58 104.16 26 858 8093 42612358

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Eye pain 1277.00 78.18 266 1650 49833 110537550
Eye irritation 366.78 78.18 90 1826 33362 110554021
Ocular hyperaemia 284.56 78.18 76 1840 39210 110548173
Photophobia 201.34 78.18 53 1863 25718 110561665
Ocular discomfort 195.88 78.18 42 1874 8491 110578892
Eyelid pain 178.79 78.18 27 1889 742 110586641
Product dose omission issue 145.58 78.18 82 1834 321700 110265683
Vision blurred 143.84 78.18 61 1855 128961 110458422
Lacrimation increased 129.11 78.18 39 1877 30911 110556472
Eye swelling 126.59 78.18 39 1877 33009 110554374
Corneal deposits 116.44 78.18 18 1898 578 110586805
Periorbital pain 115.12 78.18 16 1900 240 110587143
Therapy interrupted 99.49 78.18 36 1880 49786 110537597
Eye discharge 97.84 78.18 24 1892 8730 110578653
Foreign body sensation in eyes 97.11 78.18 20 1896 3314 110584069

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC S01XA24 SENSORY ORGANS
OPHTHALMOLOGICALS
OTHER OPHTHALMOLOGICALS
Other ophthalmologicals
FDA CS M0328210 Nerve Growth Factor
FDA EPC N0000193854 Recombinant Human Nerve Growth Factor
CHEBI has role CHEBI:39456 antiglaucoma drug
CHEBI has role CHEBI:66981 ophthalmology drug

Related Drugs by ATC class:

S01XA Other ophthalmologicals 24 drugs
acetylcysteinealteplasealumascorbic acidavacincaptad pegolciclosporindexpanthenoldiquafosolethylmorphineguaiazulenheparininosine show all 24 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Neurotrophic keratitis indication 128080005




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
High affinity nerve growth factor receptor Kinase AGONIST UNKNOWN DRUG LABEL
Tumor necrosis factor receptor superfamily member 16 Membrane receptor AGONIST UNKNOWN DRUG LABEL

External reference:

IDSource
B6E7K36KT8 UNII
4038032 VANDF
C4541383 UMLSCUI
CHEBI:757294 CHEBI
CHEMBL4297852 ChEMBL_ID
DB13926 DRUGBANK_ID
D11028 KEGG_DRUG
10381 INN_ID
C000647429 MESH_SUPPLEMENTAL_RECORD_UI
773954004 SNOMEDCT_US
773957006 SNOMEDCT_US
267667 MMSL
2104332 RXNORM

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
OXERVATE HUMAN PRESCRIPTION DRUG LABEL 1 71981-020 SOLUTION/ DROPS 20 ug OPHTHALMIC BLA 25 sections